In early studies, patients with the MCD/(C5) subtype of DLBCL treated with the combination of standard R-CHOP immunochemotherapy and ibrutinib, a first-generation inhibitor of Bruton’s tyrosine kinase (BTK), the key signaling molecule down-stream of BCR, demonstrated long-lasting remissions (7). This evidence concerns the gene BTK and diffuse large B-cell lymphoma.